Matsuo O, Tanbara Y, Okada K, Bando H, Nagoya T
Thromb Res. 1984 Dec 15;36(6):517-26. doi: 10.1016/0049-3848(84)90191-9.
Hybridoma producing a monoclonal antibody IgG1 to one-chain tissue plasminogen activator (t-PA) derived from human melanoma cells was obtained by fusion of mouse myeloma cells (SP-1) and spleen cells of mice previously immunized with purified t-PA. The monoclonal antibody reacted only with t-PA derived from the human melanoma cells (Bowes), and not with plasminogen activator purified from porcine heart or from human urine. The monoclonal antibody obtained from mouse ascites demonstrated 50 times stronger antibody activity than that of polyclonal antibody obtained from mouse serum. The monoclonal antibody bound t-PA firmly, inhibited the fibrinolytic activity of t-PA, but did not inhibit the amidolytic activity of t-PA completely. The fibrin-binding ability of t-PA was not inhibited. The binding of monoclonal antibody to the non-reduced form of t-PA did not differ from that to the reduced form of t-PA.
通过将小鼠骨髓瘤细胞(SP-1)与先前用纯化的单链组织型纤溶酶原激活剂(t-PA)免疫的小鼠脾细胞融合,获得了产生针对源自人黑素瘤细胞的单链组织型纤溶酶原激活剂(t-PA)的单克隆抗体IgG1的杂交瘤。该单克隆抗体仅与人黑素瘤细胞(鲍伊斯细胞)来源的t-PA反应,而不与从猪心或人尿中纯化的纤溶酶原激活剂反应。从小鼠腹水中获得的单克隆抗体显示出比从小鼠血清中获得的多克隆抗体强50倍的抗体活性。该单克隆抗体与t-PA紧密结合,抑制t-PA的纤溶活性,但未完全抑制t-PA的酰胺水解活性。t-PA的纤维蛋白结合能力未受抑制。单克隆抗体与非还原形式的t-PA的结合与与还原形式的t-PA的结合没有差异。